News/Events

There are many variables to consider when producing novel recombinant proteins. These variables include selection of an expression system, construct design, and scale.

There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include construct design, affinity tags, expression system, purification scheme, formulation, and characterization. Here we will focus on methods for determining protein quality.

There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include construct design, affinity tags, expression system, purification scheme, formulation, and characterization. Here we will focus on considerations for long-term storage of recombinant antigens.

There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include construct design, affinity tags, expression system, purification scheme, formulation, and characterization. Here we will focus on selecting an appropriate expression system for recombinant antigen production.

There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include expression system, purification techniques, protein tags, formulation, and assessment.

Proteos is an industry leader in the production of high-quality recombinant antibodies for drug discovery research. Here we will focus on the benefits of producing mAbs recombinantly in mammalian cells.

Proteos is an industry leader in the production of high-quality recombinant antibodies for drug discovery research. There are multiple methods for production of monoclonal antibodies, including hybridoma cell lines and recombinant protein technology. The following information will discuss some of the limitations of hybridoma production.

More than 6 million people worldwide are living with Parkinson’s Disease.  Proteos has proudly partnered with The Michael J. Fox Foundation to provide high-quality protein reagents in support of Parkinson’s disease research.

As we near this year’s final quarter, let Proteos help you achieve your drug discovery research goals for 2020.

Workflows for tackling challenging protein projects often utilize an affinity tag approach. Placement of the affinity tag is also an important decision that can influence protein expression, purification, and functionality.

During these uncertain times, we want you to know that Proteos’ labs are open and dedicated to providing critical research services. Partner with Proteos to advance your discovery research program.

Workflows for tackling challenging protein projects often utilize an affinity tag approach. Selection of the proper affinity tag prior to project initiation can be challenging yet critical to the ultimate success of the project.